Opportunity Information: Apply for PAR 20 054
The National Institutes of Health (NIH) funding opportunity titled "Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)" (Funding Opportunity Number PAR-20-054) is a discretionary grant program designed to support early-stage, hypothesis-generating research focused on transgender people. The central goal is to better understand how gender-affirming interventions, including hormones, pharmaceuticals, and surgical procedures used in gender reassignment, may influence biology and immune function in ways that could affect a persons susceptibility to HIV and other sexually transmitted infections (STIs). By emphasizing exploratory research, this FOA aims to build foundational knowledge that can inform future, larger-scale studies and eventually improve HIV and STI prevention and treatment approaches tailored to transgender communities.
This opportunity uses the NIH R21 mechanism, which is typically intended for innovative, exploratory projects that may be higher risk but have the potential to open up important new lines of inquiry. A key restriction is that clinical trials are not allowed under this announcement, meaning applicants should propose studies that do not meet NIH definitions of a clinical trial, such as testing an intervention to evaluate health-related outcomes. Instead, the FOA is oriented toward mechanistic, biological, and immunological characterization work, for example studies examining how specific gender-affirming hormone regimens might affect mucosal immunity, systemic immune markers, inflammation, microbiome-related factors, or other biologic pathways relevant to HIV acquisition and STI vulnerability. The overall intent is to clarify interactions between gender-affirming care and immune or biological processes that could influence infection risk, disease progression, or responses to prevention tools.
The funding activity category is health, and the program is associated with CFDA number 93.855. The award ceiling listed is $200,000, reflecting the smaller, exploratory nature of R21 grants. The opportunity was created on 2019-11-12, with an original closing date of 2021-05-11, indicating it was time-bound to that submission window as posted in the source information.
Eligibility is broad and includes many types of applicants. In addition to standard eligible entities such as state, county, and city or township governments, special district governments, independent school districts, and public and state-controlled institutions of higher education, the FOA allows applications from private institutions of higher education, for-profit organizations (other than small businesses), and small businesses. It also includes nonprofit organizations both with and without 501(c)(3) IRS status (when not an institution of higher education). Tribal eligibility is extensive, covering federally recognized Native American tribal governments as well as tribal organizations and Indian/Native American tribal governments that are not federally recognized. Public housing authorities and Indian housing authorities are also eligible.
The FOA explicitly highlights additional eligible applicants that NIH wants to encourage, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal government agencies, and faith-based or community-based organizations. It also allows non-domestic (non-U.S.) entities (foreign organizations), regional organizations, and applicants located in a U.S. territory or possession. Taken together, this broad eligibility structure supports participation from academic researchers, community-rooted organizations, and institutions serving populations that are often underrepresented in biomedical research, which aligns with the FOAs focus on generating needed evidence in transgender health and infectious disease prevention.
In practical terms, applicants responding to this announcement would be expected to propose research that advances understanding of immune and biological mechanisms in transgender people in the context of gender-affirming medical or surgical care, with clear relevance to HIV and STI prevention or treatment science. The emphasis on characterizing impact and susceptibility signals an interest in studies that can explain why certain risks may change, how prevention tools might work differently, or what biologic factors should be monitored, without moving into interventional clinical trial testing under this specific R21 call.Apply for PAR 20 054
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855.
- This funding opportunity was created on 2019-11-12.
- Applicants must submit their applications by 2021-05-11. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the name of this NIH funding opportunity?
The funding opportunity is titled "Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)." The Funding Opportunity Number (FON) is PAR-20-054.
What is the main purpose of this grant program?
The purpose is to support early-stage, hypothesis-generating research focused on transgender people, with an emphasis on understanding how gender-affirming interventions (including hormones, pharmaceuticals, and surgical procedures used in gender reassignment) may influence biology and immune function in ways that affect susceptibility to HIV and other sexually transmitted infections (STIs). The goal is to build foundational knowledge that can inform future, larger studies and improve HIV/STI prevention and treatment approaches tailored to transgender communities.
What type of NIH grant mechanism is used?
This opportunity uses the NIH R21 mechanism, which is intended for innovative, exploratory projects. R21 projects are often higher risk but can open up new and important lines of inquiry.
Are clinical trials allowed under this announcement?
No. Clinical trials are not allowed under this funding opportunity. Applicants should not propose studies that meet NIH definitions of a clinical trial, such as testing an intervention to evaluate health-related outcomes.
If clinical trials are not allowed, what kinds of studies are appropriate?
The announcement is oriented toward mechanistic, biological, and immunological characterization work. Examples described include studies examining how specific gender-affirming hormone regimens might affect mucosal immunity, systemic immune markers, inflammation, microbiome-related factors, or other biologic pathways relevant to HIV acquisition and STI vulnerability.
What research themes does the FOA emphasize?
The FOA emphasizes exploratory research to clarify interactions between gender-affirming care and immune or biological processes that could influence infection risk, disease progression, or responses to prevention tools for HIV and other STIs.
How does this opportunity relate to HIV and STI prevention or treatment?
The focus is on generating foundational evidence about immune and biologic mechanisms in transgender people that may shape susceptibility to HIV/STIs, affect disease progression, or influence how prevention tools work, with the long-term intent of informing better-tailored prevention and treatment approaches.
What is the funding activity category?
The funding activity category is health.
What CFDA number is associated with this program?
The program is associated with CFDA number 93.855.
What is the award ceiling for this opportunity?
The listed award ceiling is $200,000, consistent with the smaller, exploratory nature of R21 grants.
When was this opportunity created, and what was the closing date listed?
The opportunity was created on 2019-11-12. The original closing date listed is 2021-05-11, indicating it was time-bound to that submission window as posted in the provided source information.
Who is eligible to apply?
Eligibility is broad. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; for-profit organizations (other than small businesses); small businesses; nonprofit organizations with or without 501(c)(3) IRS status (when not an institution of higher education); and public housing authorities and Indian housing authorities.
Are tribal governments and tribal organizations eligible?
Yes. Eligibility includes federally recognized Native American tribal governments, tribal organizations, and Indian/Native American tribal governments that are not federally recognized.
Does NIH encourage applications from specific types of institutions or organizations?
Yes. The FOA explicitly highlights additional eligible applicants NIH wants to encourage, including Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); eligible federal government agencies; and faith-based or community-based organizations.
Are non-U.S. (foreign) organizations eligible to apply?
Yes. The FOA allows non-domestic (non-U.S.) entities (foreign organizations), regional organizations, and applicants located in a U.S. territory or possession.
Can for-profit organizations apply?
Yes. For-profit organizations (other than small businesses) are eligible, and small businesses are also eligible under the eligibility list provided.
What is the intended stage of research for this FOA?
The FOA is designed for early-stage, exploratory, hypothesis-generating research that can establish foundational knowledge and guide future larger-scale studies.
What kinds of gender-affirming interventions are within scope?
The FOA describes gender-affirming interventions including hormones, pharmaceuticals, and surgical procedures used in gender reassignment, with interest in how these interventions may influence biology and immune function relevant to HIV/STI susceptibility.
What biological or immunological areas are mentioned as examples?
Examples mentioned include mucosal immunity, systemic immune markers, inflammation, microbiome-related factors, and other biologic pathways relevant to HIV acquisition and STI vulnerability.
What is the practical expectation for applications submitted to this announcement?
Applications would be expected to propose research that advances understanding of immune and biological mechanisms in transgender people in the context of gender-affirming medical or surgical care, with clear relevance to HIV and STI prevention or treatment science, while avoiding interventional clinical trial testing under this specific R21 call.
What is the overarching long-term intent behind funding these exploratory studies?
The long-term intent is to build the evidence base needed to inform future, larger-scale studies and ultimately improve HIV and STI prevention and treatment approaches tailored to transgender communities.
Browse more opportunities from the same category: Health
Next opportunity: Scaling Up Community Led Conservation in Amboseli and Tsavo
Previous opportunity: Cancer Intervention and Surveillance Modeling Network (CISNET) (U01 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 20 054
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 20 054) also looked into and applied for these:
| Funding Opportunity |
|---|
| NEI Center Core Grant for Vision Research (P30 Clinical Trial Not Allowed) Apply for PAR 20 051 Funding Number: PAR 20 051 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improving oral health and reducing disparities in adolescents (R01 Clinical Trial Not Allowed) Apply for PAR 20 058 Funding Number: PAR 20 058 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improving oral health and reducing disparities in adolescents (R21 Clinical Trial Not Allowed) Apply for PAR 20 059 Funding Number: PAR 20 059 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for Heart, Lung, and Blood Diseases and Sleep Disorders into Practice (STIMULATE-2) (R61/R33 Clinical Trial Required) Apply for RFA HL 21 011 Funding Number: RFA HL 21 011 Agency: National Institutes of Health Category: Health Funding Amount: $485,000 |
| Enhancing Suicide Prevention in Emergency Care via Telehealth (R01 Clinical Trial Optional) Apply for RFA MH 20 226 Funding Number: RFA MH 20 226 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed) Apply for PAR 20 060 Funding Number: PAR 20 060 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Addressing Suicide Research Gaps: Aggregating and Mining Existing Data Sets for Secondary Analyses (R01 Clinical Trial Not Allowed) Apply for RFA MH 20 307 Funding Number: RFA MH 20 307 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Addressing Suicide Research Gaps: Understanding Mortality Outcomes (R01 Clinical Trial Not Allowed ) Apply for RFA MH 20 305 Funding Number: RFA MH 20 305 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Institutional Training for a Dental, Oral and Craniofacial Research Workforce (T90/R90 Clinical Trial Not Allowed) Apply for PAR 20 056 Funding Number: PAR 20 056 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Training for a Dental, Oral and Craniofacial Research Workforce (T32 Clinical Trial Not Allowed) Apply for PAR 20 044 Funding Number: PAR 20 044 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional) Apply for RFA MH 20 350 Funding Number: RFA MH 20 350 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional) Apply for RFA MH 20 351 Funding Number: RFA MH 20 351 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed) Apply for PAR 20 063 Funding Number: PAR 20 063 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| 4DN Organization and Function in Human Health and Disease (U01 Clinical Trial Not Allowed) Apply for RFA RM 20 005 Funding Number: RFA RM 20 005 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care Settings (R01 Clinical Trial Optional) Apply for RFA MH 20 505 Funding Number: RFA MH 20 505 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| New Investigator Projects on 4DN Organization and Function in Human Health and Disease (U01 Clinical Trial Not Allowed) Apply for RFA RM 20 006 Funding Number: RFA RM 20 006 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Implementation Research in HRSA Ryan White Sites: Screening and Treatment for Mental and Substance Use Disorders to Further the National Ending the HIV Epidemic (EHE) Goals (R01 Clinical Trial Optional) Apply for RFA MH 20 520 Funding Number: RFA MH 20 520 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Implementation Research in HRSA Ryan White Sites: Screening and Treatment for Mental and Substance Use Disorders to Further the National Ending the HIV Epidemic (EHE) Goals (R34 Clinical Trial Optional) Apply for RFA MH 20 521 Funding Number: RFA MH 20 521 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care Settings (R34 Clinical Trial Required) Apply for RFA MH 20 506 Funding Number: RFA MH 20 506 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Real Time Chromatin Dynamics and Function (U01 Clinical Trial Not Allowed) Apply for RFA RM 20 003 Funding Number: RFA RM 20 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 20 054", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.